SYMPTOMS | CASE COUNTS | PREVENTION | VACCINE FINDER

---

Monkeypox is a rare disease caused by an Orthopoxvirus, the same family as the virus that causes smallpox, however it is less severe. Persons with monkeypox in the current multi-country outbreak generally report having close, sustained physical contact with other people who have monkeypox. While many of those affected in the current global outbreaks are gay, bisexual, or other men who have sex with men, anyone who has been in close contact with someone who has monkeypox can get the illness. The risk to the general public is low.

Symptoms

• Rash that looks like pimples or blisters that can occur in the mouth, genital and anal areas, or other parts of the face and body like the hands, feet, and chest.

• Fever

• Headache

• Muscle and backaches

• Chills

• Exhaustion

• Swollen Lymph Nodes

Case Counts

South Dakota Case Count: 3

U.S. Case Count (CDC)

CDC Monkeypox Website: Monkeypox disease information: symptoms, transmission, and treatment.

Prevention

Take the following steps to prevent monkeypox:

• Avoid close skin-to-skin contact with people who have a rash that looks like monkeypox

• Do not handle or touch materials such as bedding, towels or clothing of a person with monkeypox

• Wash your hands often with soap and water

CDC Resources:

• What's New & Updated

• CDC Print Resources

• Frequently Asked Questions (FAQs)

• Schools, Early Care and Education Programs, and Other Settings Serving Children or Adolescents

  • Information for Teens and Young Adults

• Signs and Symptoms

• How It Spreads

• Prevention

  • Preventing Monkeypox in Congregate Settings

  • Safer Sex, Social Gatherings, and Monkeypox
    

  • Monkeypox and Safer Sex
    

• If You Are Sick with Monkeypox

  • Preventing Spread to Others
  • Isolation and Infection Control At Home

Find a vaccine

WEBINARS | HANS | TESTING | VACCINE | TREATMENT | CONTACT

---

 

• Information For Healthcare Professionals

• What Clinicians Need to Know About Monkeypox

• Infection Control Guidance

• Clinical Guidance

  • Clinical recognition

  • Case Algorithm

  • Close Contact Algorithm

  • Monitoring Exposed Persons

  • Isolation and Prevention Practices for People with Monkeypox

  • Treatment information

• Clincian FAQs

Webinars

• Monkeypox 101 Webinar

• Healthcare Webinar | Slides (10-06-2022)

Health Alerts (HANs)

• Monkeypox Health Alerts

• HAN 475: Severe Manifestations of Monkeypox among People who are Immunocompromised

• HAN 472: Monkeypox in People with HIV, Children and Adolescents, and People who are Pregnant or Breastfeeding

• HAN 471: Monkeypox Testing and Treatment

• HAN 468: Case-finding Guidance

TESTING

• Testing is currently available at Labcorp, Mayo Clinic Laboratories, Quest Diagnostics, Aegis Sciences, Sonic Healthcare USA, and SD Public Health Laboratory

• Information for Laboratory Personnel

• Monkeypox Requisition Form

• Monkeypox FAQ

• Monkeypox Guidance
  

VACCINE

Jynneos Vaccine-Eligible Persons

• Gay, bisexual, and other men who have sex with men, transgender, or nonbinary people

• People who had skin-to-skin contact with someone in a social network experiencing monkeypox activity

• People who had any of the following in the past 6 months:
  • Sex at a commercial sex venue

  • Sex in association with a large public event

• Sexual partners of people with the above risks

• People who anticipate experiencing the above risks

• Other persons deemed as having risk of being exposed to monkeypox per medical provider judgement

• People whose degree of exposure to a monkeypox case is high or intermediate

NOTE: To maximize vaccine doses given from a vial once opened, SD-DOH advocates persons who may be at increased risk for acquiring monkeypox, who do not meet the eligibility criteria above, receive vaccine.

• Jynneos Vaccine Information Statement (VIS)
• Standing Orders

• Storage

• MMWR on Use of Jynneos Vaccine

TREATMENT

The antiviral medication tecovirimat (TPOXX) is available for the treatment of patients with monkeypox infection under the expanded access investigational new drug (EA-IND). Interested providers should follow the steps below:

• Call the SD-DOH Epidemiology Team at 605-773-3737 to discuss the indication for treatment. Note: The primary indication for treatment has been lesions around the anus and genitals.

• SD-DOH will work with the patient’s medical provider and CDC Monkeypox Clinical Team for a consultation since TPOXX is only available from the Strategic National Stockpile (SNS).

• Medical providers can anticipate TPOXX delivery from the SNS ~48 hours after the order is placed. There are no supplies of TPOXX pre-positioned in South Dakota.

• Guidance on TPOXX for Treatment (CDC)

• Interim Clinical Treatment Considerations for Severe Manifestations of Mpox (CDC)

CONTACT

If you have questions or would like additional information, please contact the Epidemiology team at 605-773-3737.